Loading
A phase 1/2 trial of CCTx-001 run by Advesya SAS, not yet recruiting.
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia is a phase 1/2 interventional study registered as NCT06281847 by Advesya SAS, with 143 participants planned, started 2025-12. Conditions recorded: Acute Myeloid Leukemia, in Relapse and Acute Myeloid Leukemia Refractory. Interventions recorded: CCTx-001.
Shares Advesya and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/